4527 Stock Overview
Manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4527 from our risk checks.
Rohto Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥3,587.00 |
52 Week High | JP¥4,117.00 |
52 Week Low | JP¥2,640.50 |
Beta | -0.21 |
11 Month Change | 12.52% |
3 Month Change | 22.86% |
1 Year Change | -9.05% |
33 Year Change | 101.80% |
5 Year Change | 149.01% |
Change since IPO | 1,582.06% |
Recent News & Updates
Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors
Aug 25Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Recent updates
Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors
Aug 25Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?
Jul 11Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Jun 23Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares
Jun 10Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward
May 14These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely
Apr 03Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching
Mar 21Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year
Mar 07Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Feb 26Shareholder Returns
4527 | JP Personal Products | JP Market | |
---|---|---|---|
7D | 4.1% | 3.4% | -4.0% |
1Y | -9.1% | -8.4% | 8.8% |
Return vs Industry: 4527 matched the JP Personal Products industry which returned -8.4% over the past year.
Return vs Market: 4527 underperformed the JP Market which returned 8.8% over the past year.
Price Volatility
4527 volatility | |
---|---|
4527 Average Weekly Movement | 5.5% |
Personal Products Industry Average Movement | 5.5% |
Market Average Movement | 6.4% |
10% most volatile stocks in JP Market | 10.2% |
10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4527 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4527's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1899 | 7,259 | Yamada Kunio | www.rohto.co.jp |
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams.
Rohto Pharmaceutical Co.,Ltd. Fundamentals Summary
4527 fundamental statistics | |
---|---|
Market cap | JP¥828.14b |
Earnings (TTM) | JP¥30.33b |
Revenue (TTM) | JP¥278.03b |
27.0x
P/E Ratio2.9x
P/S RatioIs 4527 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4527 income statement (TTM) | |
---|---|
Revenue | JP¥278.03b |
Cost of Revenue | JP¥117.44b |
Gross Profit | JP¥160.59b |
Other Expenses | JP¥130.26b |
Earnings | JP¥30.33b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
Earnings per share (EPS) | 132.94 |
Gross Margin | 57.76% |
Net Profit Margin | 10.91% |
Debt/Equity Ratio | 17.8% |
How did 4527 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield20%
Payout RatioDoes 4527 pay a reliable dividends?
See 4527 dividend history and benchmarksRohto PharmaceuticalLtd dividend dates | |
---|---|
Ex Dividend Date | Sep 27 2024 |
Dividend Pay Date | Dec 09 2024 |
Days until Ex dividend | 18 days |
Days until Dividend pay date | 91 days |
Does 4527 pay a reliable dividends?
See 4527 dividend history and benchmarks